Abstract:Introduction: Siraitia grosvenorii (Swingle) C. Jeffrey, is an edible and traditional medicine widely used in China. Mogroside V (MGV) and mogrol (MG) are its main active ingredients, which have been found to be effective in the treatment of neurodegenerative diseases recently. However, whether they can effectively treat Parkinson's disease (PD) and their underlying mechanisms have not been sufficiently explored. In this study, we investigated the neuroprotective and metabolic regulatory effects of MGV and MG on PD. Materials and methods: Using SH-SY5Y cell models and an MPTP-induced mouse model of PD, we evaluated the compounds' efficacy in mitigating MPP+-induced neurotoxicity and ameliorating motor deficits and dopaminergic neuron loss. Employing widely targeted metabolomics and bioinformatics analysis to investigate the Metabolic imbalance rectification caused by MGV and MG treatment. The vivo experimental protocol encompassed a 14-day drug administration regimen with mice randomly allocated into six groups (n = 9) receiving distinct compound dosages including a control group, a model group, MGV-H (30 mg/kg/day), MGV-L (10 mg/kg/day), MG-H (15 mg/kg/day), and MG-L (3 mg/kg/day). Results: Our findings revealed that pre-treatment with MGV and MG significantly enhanced cell viability in SH-SY5Y cells exposed to MPP+, demonstrating a potent protective effect against neurotoxicity. In the MPTP mouse model, MGV-H, MGV-L, and MG-H significantly enhanced motor coordination as assessed by the rotarod test (p < 0.05); MGV-L and MG-H evidently inhibited dopaminergic neuronal loss in the substantia nigra pars compacta (p < 0.05). Furthermore, metabolomic analysis of the substantia nigra highlighted the restoration of metabolic balance, with MGV-L and MG-H impacting 160 differential metabolites and modulating key pathways disrupted in PD, including sphingolipid metabolism, fatty acid metabolism, and amino acid metabolism. Notably, treatment with MGV-L and MG-H led to the regulation of 106 metabolites, showing a recovery trend towards normal levels, which constitutes approximately 17.5% of the identified metabolites. Key metabolites such as n-acetyl-l-glutamate, hexadecanoic acid, and 9-octadecenal were significantly altered (p < 0.05), underscoring their broad-spectrum metabolic regulatory capacity. Conclusion: This study underscores the potential of natural compounds in developing comprehensive treatment strategies for neurodegenerative diseases, paving the way for future clinical research to validate the therapeutic efficacy of mogrosides in PD.

Functional study of natural food sweetener mogrosides

The Pharmacokinetic Profiles of Mogrosides in T2DM Rats.

A Study on the Aperient and Anti-inflammatory Effect of Mogrosides

Recent advancements in mogrosides: A review on biological activities, synthetic biology, and applications in the food industry

Effect of Mulberry Leaves Extract on Mice Blood Glucose Level and the Mensuration of Its Active Components

Protective Activity of Mogroside V Against Ovalbumin-Induced Experimental Allergic Asthma in Kunming Mice

Hypoglycemic effect of polysaccharides in Ramulus Mori on diabetic model mice

The Metabolism of a Natural Product Mogroside V, in Healthy and Type 2 Diabetic Rats.

Regulating the Gut Microbiota and SCFAs in the Faeces of T2DM Rats Should Be One of Antidiabetic Mechanisms of Mogrosides in the Fruits of Siraitia Grosvenorii

Mogrol stimulates G-protein-coupled bile acid receptor 1 (GPBAR1/TGR5) and insulin secretion from pancreatic β-cells and alleviates hyperglycemia in mice

Study on the Hypoglycemic Mechanism of Tea Polysaccharides and Tea Polyphenols

Effects of Female Silkworm Moth Powder on Antioxidation Levels in Alloxan-induced Mice

Mogroside V alleviates inflammation response by modulating miR-21-5P/SPRY1 axis

Screening of bioactive flavour compounds targeting muscarinic-3 acetylcholine receptor from Siraitia grosvenorii and evaluation of their synergistic anti-asthmatic activity

Mogroside V and mogrol: unveiling the neuroprotective and metabolic regulatory roles of Siraitia grosvenorii in Parkinson's disease

Natural Sweetener Glycyrrhetinic Acid Monoglucuronide Improves Glucose Homeostasis in Healthy Mice

Mogroside V reduce OVA-induced pulmonary inflammation based on lung and serum metabolomics

The protective effects of Mogroside V and its metabolite 11-oxo-mogrol of intestinal microbiota against MK801-induced neuronal damages

Mogroside V and Mogrol: Unveiling the Neuroprotective and Metabolic Regulatory Roles of Siraitia Grosvenorii in Parkinson’s Disease

Hypoglycemic Effect of the Polysaccharide from Dendrobium Moniliforme(l.)sw

Development of New Multi-Glycosylation Routes to Facilitate the Biosynthesis of Sweetener Mogrosides from Bitter Immature Siraitia Grosvenorii Using Engineered Escherichia coli